The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease

Background & Aims Macrophage activation plays a key pathogenic role in experimental non‐alcoholic fatty liver disease (NAFLD) and contributes to the progression of steatohepatitis (NASH) and fibrosis. We studied macrophage activation in human NAFLD by measuring soluble (s)CD163, a specific macro...

Full description

Saved in:
Bibliographic Details
Published inLiver international Vol. 36; no. 10; pp. 1549 - 1557
Main Authors Kazankov, Konstantin, Barrera, Francisco, Møller, Holger Jon, Rosso, Chiara, Bugianesi, Elisabetta, David, Ezio, Ibrahim Kamal Jouness, Ramy, Esmaili, Saeed, Eslam, Mohammed, McLeod, Duncan, Bibby, Bo Martin, Vilstrup, Hendrik, George, Jacob, Grønbæk, Henning
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.10.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background & Aims Macrophage activation plays a key pathogenic role in experimental non‐alcoholic fatty liver disease (NAFLD) and contributes to the progression of steatohepatitis (NASH) and fibrosis. We studied macrophage activation in human NAFLD by measuring soluble (s)CD163, a specific macrophage activation marker, hypothesizing that sCD163 would be associated with the patients’ morphological disease grade. Furthermore, we investigated an association between sCD163 and the apoptosis marker cytokeratin‐18 (CK‐18) to explore a link between macrophage activation and apoptosis. Methods sCD163 associations with biochemical and histological measures of NAFLD were investigated in two independent cohorts of 157 Australian and 174 Italian NAFLD patients, with liver biopsies graded for NAFLD severity, steatosis and fibrosis. sCD163 and CK‐18 were measured by enzyme‐linked immunosorbent assay. Results In both cohorts sCD163 increased in parallel with the patients’ morphological disease grading, being independently associated with the Kleiner fibrosis score (P < 0.001). A high sCD163 predicted advanced fibrosis {F ≥ 3; Australian cohort: area under receiver‐operating characteristics curve 0.77 [95% confidence interval (CI): 0.76–0.87], Italian cohort: 0.80 (95% CI: 0.72–0.88)}. In both groups, sCD163 was independently associated with CK‐18 (P < 0.001). Conclusion Soluble CD163 reflecting macrophage activation is associated with morphological features of NAFLD suggesting their involvement in the pathogenesis of NAFLD, NASH and particularly fibrosis. An independent association between sCD163 and cytokeratin‐18 suggests that apoptosis may contribute to macrophage activation in NAFLD/NASH.
Bibliography:NOVO Nordisk Foundation
Sydney Medical Foundation, University of Sydney
project FLIP - No. PRIN 2009ARYX4T
istex:18FD2BCC44BE3839A8BC2F57B0119AB4B25AA520
FP7/2007-2013 - No. HEALTH-F2-2009-241762
ArticleID:LIV13150
The Danish Strategic Research Council - No. 10-092797
Savværksejer Jeppe Juhl og hustru Ovita Juhls mindelegat
National Health and Medical Research Council of Australia (NHMRC) Program Grant - No. 1053206; No. 632630; No. 1049857
ark:/67375/WNG-ZWV1SRNF-7
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.13150